Emerging Medical Treatments for Meningioma in the Molecular Era

Fares Nigim, Hiroaki Wakimoto*, Ekkehard M. Kasper, Linda Ackermans, Yasin Temel

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

21 Citations (Web of Science)

Abstract

Meningiomas are the most common type of primary central nervous system tumors. Approximately, 80% of meningiomas are classified by the World Health Organization (WHO) as grade I, and 20% of these tumors are grade II and III, considered high-grade meningiomas (HGMs). Clinical control of HGMs, as well as meningiomas that relapse after surgery, and radiation therapy is difficult, and novel therapeutic approaches are necessary. However, traditional chemotherapies, interferons, hormonal therapies, and other targeted therapies have so far failed to provide clinical benefit. During the last several years, next generation sequencing has dissected the genetic heterogeneity of meningioma and enriched our knowledge about distinct oncogenic pathways driving different subtypes of meningiomas, opening up a door to new personalized targeted therapies. Molecular classification of meningioma allows a new design of clinical trials that assign patients to corresponding targeted agents based on the tumor genetic subtypes. In this review, we will shed light on emerging medical treatments of meningiomas with a particular focus on the new targets identified with genomic sequencing that have led to clinical trials testing novel compounds. Moreover, we present recent development of patient-derived preclinical models that provide platforms for assessing targeted therapies as well as strategies with novel mechanism of action such as oncolytic viruses.
Original languageEnglish
Article number86
Number of pages21
JournalBiomedicines
Volume6
Issue number3
DOIs
Publication statusPublished - 1 Sep 2018

Keywords

  • World Health Organization (WHO)
  • Grade I
  • II
  • and III Meningiomas
  • High Grade Meningiomas (HGMs)
  • tumor heterogeneity
  • genetic subtypes
  • overall survival (OS)
  • progression free survival (PFS)
  • targeted therapy
  • clinical trials
  • oncolytic virus (OV)
  • TERT PROMOTER MUTATIONS
  • GROWTH-FACTOR RECEPTOR
  • FOCAL-ADHESION KINASE
  • TUMOR-SUPPRESSOR GENE
  • HERPES-SIMPLEX-VIRUS
  • SKULL BASE MENINGIOMAS
  • OF-THE-LITERATURE
  • PHASE-II TRIAL
  • INTEGRATIVE GENOMIC ANALYSIS
  • PLECKSTRIN HOMOLOGY DOMAIN
  • RECURRENT MENINGIOMAS
  • SONIC HEDGEHOG PATHWAY

Cite this